CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
Oxycodone Tamper Resistant +1 moredrug
Likely dose
Oxycodone Tamper Resistant 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03403504
NCT03403504Phase 1Completed

An Open-label, Single Dose, Randomised, Cross-over Study to Determine the Fasted State Pharmacokinetics of Oxycodone From Oxycodone Tamper Resistant (OTR) Tablet 10 mg and OXYCONTIN® Tablet 10 mg in Chinese Subjects With Chronic Pain

Mundipharma (China) Pharmaceutical Co. Ltd·interventional·Posted Jan 18, 2018·Updated Jan 31, 2020

In Brief

A Phase 1 clinical trial evaluating Oxycodone Tamper Resistant and OXYCONTIN® for Chronic Pain. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This is an open-label, single Dose, randomised, cross-over study to confirm the bioequivalence (BE) of OTR tablet 10 mg and OXYCONTIN tablet 10 mg in a fasted state in Chinese subjects with chronic pain

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pain
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 18, 2018
Enrollment StartFeb 1, 2017
Primary CompletionJul 24, 2017
Study CompletionSep 7, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.5 years ago

Interventions

Oxycodone Tamper Resistantdrug

Orally administered Oxycodone Tamper Resistant 10mg

OXYCONTIN®drug

Orally administered OXYCONTIN® Tablet 10 mg